Subtype
Esophageal Carcinoma
CI-CAN-00002609ESCAExplore in graph →
307 active trials4 approved drugs11 evidence items
- NCIt
- C3513
- DOID
- 1107
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002609ESCAExplore in graph →
Clinical trials
807 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (62)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04921904 | Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca | completed | Phase 1 / Phase 2 | 26 | Baylor Research InstituteOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05411133 | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | completed | Phase 1 | 33 | Arbele Pty LtdINDUSTRY | 2 | Mar 19, 2026 | clinicaltrials |
| NCT03008278 |
| Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery |
| completed |
| Phase 1 / Phase 2 |
| 51 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Feb 3, 2026 |
| clinicaltrials |
| NCT04045496 | A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 40 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT05342636 | A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) | completed | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Dec 17, 2025 | clinicaltrials |
| NCT06549816 | A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors | completed | Phase 1 | 6 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Dec 15, 2025 | clinicaltrials |
| NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 19 | CRISPR Therapeutics AGINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT03708328 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 134 | Hoffmann-La RocheINDUSTRY | 6 | Aug 20, 2025 | clinicaltrials |
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | Incyte CorporationINDUSTRY | 5 | Jul 14, 2025 | clinicaltrials |
| NCT01351103 | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | completed | Phase 1 | 185 | Novartis PharmaceuticalsINDUSTRY | 7 | Jun 13, 2025 | clinicaltrials |
| NCT03914443 | A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma | completed | Phase 1 | 37 | National Cancer Center, JapanOTHER_GOV | 1 | May 31, 2025 | clinicaltrials |
| NCT04121286 | A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China | completed | Phase 1 | 17 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | May 20, 2025 | clinicaltrials |
| NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | completed | Phase 1 | 269 | ExelixisINDUSTRY | 9 | Apr 4, 2025 | clinicaltrials |
| NCT04713891 | A Study of KF-0210 in Advanced Solid Tumors Patients | completed | Phase 1 | 14 | Keythera Pharmaceuticals (Australia) Pty LtdINDUSTRY | 1 | Sep 24, 2024 | clinicaltrials |
| NCT04721223 | JAB-3068 Activity in Adult Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 12 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06184841 | HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma | completed | Phase 1 | 25 | Peking University Cancer Hospital & InstituteOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT03792347 | Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus(PALACE-1) | completed | Phase 1 | 20 | Hecheng Li M.D., Ph.DOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT03888092 | Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification | completed | Phase 1 / Phase 2 | 81 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Mar 21, 2023 | clinicaltrials |
| NCT02645864 | Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma | completed | Phase 1 | 12 | Peking UniversityOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT01598077 | A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer | completed | Phase 1 | 54 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 19, 2020 | clinicaltrials |
| NCT01822613 | Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) | completed | Phase 1 | 48 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 19, 2020 | clinicaltrials |
| NCT02658214 | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 2 | Aug 20, 2020 | clinicaltrials |
| NCT02120911 | Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma(TRAP) | completed | Phase 1 / Phase 2 | 40 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT02964455 | Study of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 1 | 12 | Sun Yat-sen UniversityOTHER | 1 | May 15, 2020 | clinicaltrials |
| NCT01561014 | Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction | completed | Phase 1 | 9 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01231399 | Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer | completed | Phase 1 / Phase 2 | 6 | City of Hope Medical CenterOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT01391208 | Esophageal Protocol for Detection of Neoplasia in the Digestive Tract | completed | Phase 1 | 25 | University of MichiganOTHER | 1 | Oct 11, 2012 | clinicaltrials |
| NCT00423254 | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. | completed | Phase 1 | 12 | Mannkind CorporationINDUSTRY | 1 | Aug 3, 2010 | clinicaltrials |
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials